A phase 1/2 clinical trial is a single study that combines two normally separate stages of drug testing into one protocol. Instead of running a phase 1 trial to find a safe dose, pausing, then launching a separate phase 2 trial to test whether the drug works, researchers do both in sequence within the same study. This saves time and can get promising treatments to patients faster, which is why it has become common in cancer research and rare diseases.
How Standard Clinical Phases Work
To understand why combining phases matters, it helps to know what each phase normally does on its own. A standard phase 1 trial enrolls 20 to 100 volunteers and focuses almost entirely on safety. Researchers start with a very low dose and gradually increase it, watching for side effects at each level, until they identify the highest dose patients can tolerate without unacceptable harm. That ceiling is called the maximum tolerated dose, or MTD.
A standard phase 2 trial then takes that dose and tests it in a larger group, typically a few hundred patients who have the disease the drug is meant to treat. The goal shifts from “is this safe?” to “does this actually work?” Researchers measure things like how many tumors shrink (the objective response rate), how long patients go without their disease getting worse, or other signs that the treatment is having a real effect.
Running these as separate trials means there is a gap between them. The phase 1 team publishes results, a new protocol gets written and approved, new patients are recruited, and the clock resets. That gap can add months or even years to the development timeline.
What Changes in a Combined Design
In a phase 1/2 trial, the study protocol is written from the start to cover both objectives. The trial typically begins with a dose-escalation portion that looks like a traditional phase 1: small groups of patients receive increasing doses, and researchers track side effects to identify the MTD. Once a safe and promising dose is established, the trial transitions into an expansion portion where more patients are enrolled at that dose to evaluate whether the drug is effective.
The transition between these portions happens within the same study, under the same regulatory approval, often at the same research sites. Patients enrolled in the early dose-finding portion may even contribute data to the efficacy analysis later on. This seamless handoff is the core advantage of the design.
Expansion cohorts in these trials typically enroll additional patients at the recommended dose, sometimes focusing on specific disease subtypes or patients with particular genetic markers. Research involving 381 anticancer drugs found that phase 1 trials with expansion cohorts of 2 to 20 patients were roughly twice as likely to lead to a successful phase 2 outcome compared to trials with no expansion cohorts. Disease-specific trials, where only patients with a particular cancer type are enrolled, also showed higher success rates downstream.
How Dose Decisions Are Made
The dose-escalation portion of a phase 1/2 trial uses structured rules to protect patients while gathering useful data. The most traditional approach is called the 3+3 design: three patients receive a dose level, and if none experience a serious side effect (called a dose-limiting toxicity), the next three patients get a higher dose. If one of the three has a serious side effect, three more patients are added at the same dose. If too many patients at a given level have problems, escalation stops.
More modern designs use statistical models to make smarter decisions. The continuous reassessment method uses accumulating safety data to estimate the probability of toxicity at each dose and recommends the next dose accordingly, rather than following rigid rules. Newer Bayesian designs go a step further by weighing both toxicity and efficacy simultaneously. Instead of simply finding the highest tolerable dose, these models identify what researchers call the optimal biological dose: the dose that provides the best balance between benefit and harm. This is especially relevant for targeted therapies and immunotherapies, where the most effective dose is not always the highest one the body can handle.
Why They Are Common in Oncology and Rare Diseases
Phase 1/2 designs show up most frequently in cancer drug development. In oncology, phase 1 trials already enroll patients with the disease rather than healthy volunteers, because the drugs are too toxic to give to healthy people. That means safety and early efficacy data can be collected from the same patient population, making a combined design a natural fit. Many oncology research groups run roughly equal numbers of standalone phase 1 and combined phase 1/2 trials.
Rare diseases are the other major area where these designs thrive. When only a small number of patients exist worldwide, running separate sequential trials is impractical. Combining phases allows researchers to gather safety and efficacy evidence from a smaller total number of participants. Drug manufacturers use this approach specifically to compress development timelines for conditions where patient recruitment is a bottleneck.
What Researchers Measure
The primary endpoints in a phase 1/2 trial reflect its dual purpose. During the dose-escalation phase, the main endpoint is typically the rate of dose-limiting toxicities, which determines the maximum tolerated dose. During the expansion or efficacy phase, the primary endpoint shifts to a measure of whether the drug is working.
In cancer trials, the most common efficacy endpoint is the objective response rate: the percentage of patients whose tumors shrink by a meaningful amount. The FDA has accepted this measure as the basis for drug approval across dozens of cancer types, from breast cancer and lung cancer to lymphoma and leukemia. Other endpoints can include how long responses last, how long patients survive without disease progression, or biomarker changes that signal the drug is hitting its target.
What Participation Looks Like
If you are considering enrolling in a phase 1/2 trial, it helps to know which portion you would be entering. Patients in the dose-escalation phase face more uncertainty. The right dose has not yet been established, and you may receive a dose that turns out to be too low to be effective or high enough to cause significant side effects. Monitoring during this phase is intensive, with frequent blood draws, imaging, and clinic visits.
Patients in the expansion phase receive a dose that earlier participants have already tolerated, so there is more safety data available. Monitoring is still close, but the experience is somewhat closer to a standard phase 2 trial. Total enrollment across both portions of a phase 1/2 trial can range from a few dozen patients in the escalation phase to a hundred or more once expansion cohorts are included.
Because these are early-stage trials, the drug has not yet been proven to work. The treatment may ultimately show no benefit, and side effects that were not seen in earlier patients can still emerge. But for patients with serious conditions who have exhausted standard options, phase 1/2 trials offer access to experimental therapies that would otherwise take years longer to reach them through the conventional development pipeline.